TXG — 10x Genomics, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1770787 ·
Last close
$42.73
Market Cap
$4.99B
52W High
$43.23
52W Low
$19.53
ADV30
3,395,344
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 150,843,000 | 106,178,000 | -17,046,000 | -13,470,000 | 1,015,759,000 | 490,285,000 | 201,435,000 |
| Dec 2025 | 166,030,000 | 113,045,000 | -19,541,000 | -16,252,000 | 1,041,365,000 | 473,966,000 | 245,039,000 |
| Sep 2025 | 149,002,000 | 100,307,000 | -32,242,000 | -27,472,000 | 1,027,361,000 | 432,508,000 | 242,241,000 |
| Jun 2025 | 172,908,000 | 125,084,000 | -10,574,000 | 34,538,000 | 979,970,000 | 397,712,000 | 206,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$127,819,000
Investing CF
$-12,856,000
Financing CF
$-2,036,000
CapEx
$-5,639,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.17
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,524,061,000
Inventory
$53,487,000
Receivables
$56,137,000
ST Investments
$49,563,000
EBIT TTM
$39,149,000
Pretax Income TTM
$-19,248,000
Interest Exp TTM
$3,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$638,782,976
EBITDA
$-30,669,000
Free Cash Flow
$124,545,128
Enterprise Value
$5,013,352,960
Total Cash
$539,848,000
Total Debt
$81,389,000
Shares Out
116,877,317
Trailing EPS
$-0.17
Book Value
$6.24
ROE
-3.0%
ROA
-4.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 642,823,000 | -110,885,000 | -43,544,000 | 1,041,365,000 | 245,039,000 | — | 136,050,000 |
| Dec 2024 | 610,785,000 | -194,559,000 | -182,627,000 | 918,636,000 | 208,502,000 | — | 6,664,000 |
| Dec 2023 | 618,727,000 | -204,349,000 | -255,099,000 | 965,143,000 | 224,100,000 | — | -15,197,000 |
| Dec 2022 | 516,409,000 | -167,944,000 | -166,000,000 | 1,028,980,000 | 223,237,000 | — | -33,606,000 |
TTM Snapshot
Revenues TTM
$563,117,000
NetIncome TTM
$-189,968,000
OpCashFlow TTM
$0
Assets (Latest)
$918,636,000
Forward EPS
$0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RKGRY | RENK Group AG/ADR | $5.00B | $10.00 | — |
| CHWRF | China Tower Corp Limited/ADR | $5.00B | $1.10 | — |
| G | Genpact LTD | $4.98B | $29.37 | — |
| OGS | ONE Gas, Inc. | $4.97B | $79.17 | — |
| ATDRF | Auto Trader Group plc/ADR | $5.05B | $6.43 | — |
News headlines (Yahoo Finance, 1h cache)
Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story?
2026-07-10 04:32 · Yahoo
Is 10x Genomics (TXG) Overvalued Following Its Earnings Beat?
2026-07-09 16:11 · Yahoo
3 Cash-Heavy Stocks We Find Risky
2026-07-09 10:37 · Yahoo
10x Genomics (TXG) Stock Looks Reasonable On Cash Flow But Rich On Sales
2026-07-09 09:11 · Yahoo
Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)
2026-07-08 15:22 · Yahoo
1 Unprofitable Stock on Our Watchlist and 2 We Brush Off
2026-07-06 12:04 · Yahoo
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor
2026-06-26 20:48 · Yahoo
Why Is 10x Genomics (TXG) Stock Soaring Today
2026-06-24 18:16 · Yahoo
10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics
2026-06-19 14:31 · Yahoo
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings?
2026-06-19 10:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.